Zobrazeno 1 - 10
of 52
pro vyhledávání: '"W H, Utian"'
Autor:
J. Douxfils, U. Gaspard, M. Taziaux, M. Jost, C. Bouvy, R. A. Lobo, W. H. Utian, J.-M. Foidart
OBJECTIVE: This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids, carbohydrate metabolism and bone turnover in postmenopausal women.METHODS: This study was a multicenter, randomized, double-blind placebo-controlled phase 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb5dc18dcfe4776e6b05888a548243be
Autor:
W. H. Utian
Publikováno v:
Progress in the Management of the Menopause ISBN: 9781003076575
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23cb61417f8efc9563a4f5ecd2be758
https://doi.org/10.1201/9781003076575-1
https://doi.org/10.1201/9781003076575-1
Autor:
M. Omizo, Michael A. Bolognese, S. Broy, Mark Lakshmanan, R. Feldman, W. H. Utian, D. L. Meats, John H. Krege, Jahangir Alam
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 94:2284-2289
Introduction: Arzoxifene, a benzothiophene estrogen agonist/antagonist, is being developed for prevention and treatment of osteoporosis and for risk reduction of invasive breast cancer in postmenopausal women. Methods: The effects of arzoxifene 20 mg
Autor:
W. H. Utian
INTRODUCTION Quality of life (QOL) is increasingly being recognized as a key outcome measure of quality of health-care. There is considerable evidence that the complications of osteoporosis will have a negative impact on QOL. However, less well recog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a00918653456cbaf703abe32cb34131
https://doi.org/10.1201/b14631-5
https://doi.org/10.1201/b14631-5
Autor:
W H, Utian
Publikováno v:
Climacteric : the journal of the International Menopause Society. 2(4)
Autor:
W H, Utian, K A, Burry, D F, Archer, J C, Gallagher, R L, Boyett, M P, Guy, G J, Tachon, H K, Chadha-Boreham, A A, Bouvet
Publikováno v:
American journal of obstetrics and gynecology. 181(1)
Our purpose was to evaluate the efficacy and safety of 3 dosages of Esclim, delivering 0.025 mg, 0.050 mg, or 0.100 mg 17beta-estradiol per 24 hours, in the treatment of moderate to severe vasomotor symptoms.In this double-blind, placebo-controlled,
Autor:
W H, Utian, P P, Boggs
Publikováno v:
Menopause (New York, N.Y.). 6(2)
To collect information relevant to the mission of The North American Menopause Society (NAMS)--i.e., increasing understanding of menopause--by assessing perceptions held by postmenopausal women in the United States aged 50 to 65 years regarding their
Autor:
W H, Utian
Publikováno v:
Menopause (New York, N.Y.). 6(2)
Publikováno v:
Menopause (New York, N.Y.). 5(4)
The main purpose in organizing this survey was to collect information relevant to The North American Menopause Society's (NAMS) educational mission and to document women's knowledge of, and attitudes toward, menopause.During June-July 1997, The Gallu